Published in Ann Intern Med on September 21, 2010
Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med (2014) 2.31
At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer (2009) 1.88
A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making (2011) 1.77
Increasing colon cancer screening in primary care among African Americans. J Natl Cancer Inst (2014) 1.53
Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med (2012) 1.52
Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population. Clin Epidemiol (2017) 1.37
Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev (2014) 1.07
The value of models in informing resource allocation in colorectal cancer screening: the case of the Netherlands. Gut (2015) 0.87
Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications. Med Decis Making (2016) 0.85
Review of economic evidence in the prevention and early detection of colorectal cancer. Health Econ Rev (2013) 0.84
Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. Clin Gastroenterol Hepatol (2016) 0.83
Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection. Int J Cancer (2014) 0.81
Colorectal cancer and Crohn's colitis: clinical implications from 313 surgical patients. World J Surg (2013) 0.80
Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity. Cancer (2016) 0.79
Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions. Med Decis Making (2012) 0.79
Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information. Med Decis Making (2012) 0.79
A simulation model of colorectal cancer surveillance and recurrence. BMC Med Inform Decis Mak (2014) 0.79
A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer. Br J Cancer (2016) 0.78
Colorectal cancer surveillance: what's new and what's next. World J Gastroenterol (2014) 0.78
Computer disease simulation models: integrating evidence for health policy. Acad Radiol (2011) 0.77
Simulation of colorectal cancer screening: what we do and do not know and does it matter. Best Pract Res Clin Gastroenterol (2010) 0.77
A framework for evaluating the cost-effectiveness of patient decision aids: A case study using colorectal cancer screening. Prev Med (2015) 0.77
Colorectal Cancer Screening: Stool DNA and Other Noninvasive Modalities. Gut Liver (2016) 0.75
Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. PLoS One (2017) 0.75
Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 16.82
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86
Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology (2003) 14.67
Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med (2000) 13.21
The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med (2000) 13.19
Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med (2006) 8.18
Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst (1999) 8.08
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology (2007) 7.16
Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med (2004) 6.42
Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol (2006) 6.03
Cost-effectiveness of screening for colorectal cancer in the general population. JAMA (2000) 5.88
Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med (2006) 5.10
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology (2006) 4.57
Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst (2000) 3.92
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst (2007) 3.80
The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology (1990) 3.72
Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev (2008) 3.64
American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin (2006) 3.46
Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med (2009) 3.34
Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut (1982) 3.23
The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer (1982) 2.85
Adenomatous polypi of large intestine: incidence and distribution. Ann Surg (1963) 2.74
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology (2005) 2.71
Patient preferences for colorectal cancer screening: how does stool DNA testing fare? Am J Manag Care (2007) 2.60
INCIDENCE AND DISTRIBUTION OF ADENOMATOUS POLYPS OF THE COLON AND RECTUM BASED ON 1,000 AUTOPSY EXAMINATIONS. Dis Colon Rectum (1964) 2.54
Adenomatous lesions of the large bowel: an autopsy survey. Cancer (1979) 2.41
Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer (1986) 2.22
Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut (1992) 2.15
Current status of screening colonoscopy in Europe and in the United States. Endoscopy (2007) 2.14
Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer (1985) 2.08
Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol (2006) 1.99
The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res (1999) 1.98
Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol (1989) 1.79
Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer (1988) 1.57
Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology (2004) 1.49
A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol (2008) 1.40
A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer (2009) 1.37
Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer (2003) 1.35
Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn (2004) 1.11
Visualizing cost-effectiveness analysis. JAMA (2002) 1.08
Complications of screening flexible sigmoidoscopy. Gastroenterology (2002) 1.07
Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer (2006) 1.04
Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. Am J Gastroenterol (2007) 1.04
Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer (2006) 0.99
Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am J Prev Med (2005) 0.90
Stool DNA testing and colon cancer prevention: another step forward. Ann Intern Med (2008) 0.84
Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med (2012) 16.55
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med (2002) 7.00
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 6.99
Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med (2007) 6.98
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 6.54
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol (2011) 5.72
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology (2006) 4.57
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Association between lymph node evaluation for colon cancer and node positivity over the past 20 years. JAMA (2011) 3.41
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin (2006) 3.21
Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst (2010) 3.05
Estimating the energy gap among US children: a counterfactual approach. Pediatrics (2006) 2.93
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Cost-effectiveness of antibiotic prophylaxis for dental patients with prosthetic joints: Comparisons of antibiotic regimens for patients with total hip arthroplasty. J Am Dent Assoc (2015) 2.60
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology (2008) 2.56
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut (2013) 2.50
Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol (2007) 2.49
Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) (2008) 2.47
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) (2009) 2.46
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev (2012) 2.39
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst (2009) 2.35
Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med (2014) 2.31
Cost-effectiveness of colorectal cancer screening. Epidemiol Rev (2011) 2.24
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Statin use and the risk of breast and prostate cancer. Epidemiology (2002) 2.15
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health (2012) 2.14
Forecasting the obesity epidemic in the aging U.S. population. Obesity (Silver Spring) (2007) 2.09
Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ (2012) 2.05
Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging (2007) 2.00
Individualizing colonoscopy screening by sex and race. Gastrointest Endosc (2009) 1.96
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst (2009) 1.89
At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer (2009) 1.88
Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst (2012) 1.87
National Polyp Study data: evidence for regression of adenomas. Int J Cancer (2004) 1.83
Incidence of cervical cancer after several negative smear results by age 50: prospective observational study. BMJ (2009) 1.81
A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making (2011) 1.77
Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol (2007) 1.73
The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am (2002) 1.73
Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy. Gastrointest Endosc (2011) 1.72
Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making (2011) 1.71
Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr (2013) 1.71
Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am J Gastroenterol (2011) 1.66
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making (2012) 1.61
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila) (2011) 1.57
Colonoscopy surveillance after polypectomy and colorectal cancer resection. Am Fam Physician (2008) 1.52
Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med (2012) 1.52
Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics (2009) 1.48
Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer (2006) 1.45
Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. Value Health (2011) 1.44
Impact of preoperative staging and chemoradiation versus postoperative chemoradiation on outcome in patients with rectal cancer: a decision analysis. J Natl Cancer Inst (2004) 1.42
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr (2007) 1.39
A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer (2009) 1.37
Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care (2008) 1.37
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer (2007) 1.37
Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys (2008) 1.36
Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst (2011) 1.33
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Flat adenomas in the National Polyp Study: is there increased risk for high-grade dysplasia initially or during surveillance? Clin Gastroenterol Hepatol (2004) 1.32
Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant (2013) 1.30
Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer (2007) 1.30
Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect Prev (2007) 1.25
Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst (2012) 1.25
Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst (2002) 1.24
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making (2012) 1.24
Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev (2009) 1.23
Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) (2010) 1.20